UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR Her2 inhibitor in non-small-cell lung cancer cells

British journal of cancer, 2009-03, Vol.100 (6), p.941-949

2009

Volltextzugriff (PDF)

Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE

Annals of oncology, 2021-08, Vol.32 (8), p.1005-1014

2021

Volltextzugriff (PDF)

Activation (Tyrosine Phosphorylation) of ErbB-2 (HER-2/neu): A Study of Incidence and Correlation With Outcome in Breast Cancer

Journal of clinical oncology, 2000-09, Vol.18 (18), p.3230-3239

2000

Volltextzugriff (PDF)

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

The New England journal of medicine, 2019-02, Vol.380 (7), p.617-628

2019

Volltextzugriff (PDF)

Active signaling by Neu in transgenic mice

Oncogene, 1998-10, Vol.17 (14), p.1877-1884

1998

Volltextzugriff (PDF)

Adenoid cystic carcinoma: A retrospective clinical review

International journal of cancer, 2001-06, Vol.96 (3), p.149-158

2001

Volltextzugriff (PDF)

Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours

British journal of cancer, 1996-09, Vol.74 (5), p.802-806

1996

Volltextzugriff (PDF)

Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: Clinicopathological correlates

Cancer research (Chicago, Ill.), 2002-11, Vol.62 (22), p.6667-6673

2002

Volltextzugriff (PDF)

Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor

Cancer research (Chicago, Ill.), 1995-05, Vol.55 (9), p.1946-1955

1995

Volltextzugriff (PDF)

Pathobiologic Findings in DCIS of the Breast: Morphologic Features, Angiogenesis, HER-2/neu and Hormone Receptors

Experimental and molecular pathology, 2001-06, Vol.70 (3), p.303-316

2001

Volltextzugriff (PDF)

Drugs targeting insulin-like growth factor 1 receptor

Breast cancer online, 2009-04, Vol.12 (4), Article e7

2009

Volltextzugriff (PDF)

Relationship of Epidermal Growth Factor Receptor Expression to ErbB-2 Signaling Activity and Prognosis in Breast Cancer Patients

Journal of clinical oncology, 2005-02, Vol.23 (6), p.1152-1160

2005

Volltextzugriff (PDF)

Neoadjuvant Trastuzumab Induces Apoptosis in Primary Breast Cancers

Journal of clinical oncology, 2005-04, Vol.23 (11), p.2460-2468

2005

Volltextzugriff (PDF)

Self-Management and Transitions in Women With Advanced Breast Cancer

Journal of pain and symptom management, 2011-10, Vol.42 (4), p.517-525

2011

Volltextzugriff (PDF)

Sequence of Radiotherapy With Tamoxifen in Conservatively Managed Breast Cancer Does Not Affect Local Relapse Rates

Journal of clinical oncology, 2005-01, Vol.23 (1), p.17-23

2005

Volltextzugriff (PDF)

Abstract GS1-10: Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.GS1-10-GS1-10

2019

Volltextzugriff (PDF)

Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin)

Clinical cancer research, 2004-02, Vol.10 (4), p.1409-1420

2004

Volltextzugriff (PDF)

Abstract P5-11-03: Development of an interactive text messaging tool to improve adherence with adjuvant endocrine therapy: Breast cancer endocrine therapy adherence (BETA) pilot study

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P5-P5-11-03

2016

Volltextzugriff (PDF)

Production of Antibodies That Recognize Specific Tyrosine‐Phosphorylated Peptides

Current protocols in molecular biology (Print), 2001-05, Vol.50 (1), p.18.6.1-18.6.19

2001

Volltextzugriff (PDF)

Association between HER2/neu overexpression and calcifications in breast cancer

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.579-579

2009

Volltextzugriff (PDF)

Histologic subtypes of ductal intraepithelial neoplasia (DIN) of the breast: Characteristic associations and biology

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.633-633

2009

Volltextzugriff (PDF)

Characterization of the HER-2/neu Oncogene by Immunohistochemical and Fluorescence in Situ Hybridization Analysis in Oral and Oropharyngeal Squamous Cell Carcinoma

Clinical cancer research, 2002-02, Vol.8 (2), p.540-548

2002

Volltextzugriff (PDF)

In vitro and in vivo effects of combination of trastuzumab (Herceptin) and tamoxifen in breast cancer

Breast cancer research and treatment, 2005-08, Vol.92 (3), p.251-263

2005

Volltextzugriff (PDF)

Abstract P3-14-17: Trastuzumab (H) and Rapamycin (R) for Treatment of HER-2 Overexpressing Metastatic Breast Cancer (BC) with Prior Disease Progression on H Based Therapy: Safety and Pharmacodynamic (PD) Results

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.P3-P3-14-17

2010

Volltextzugriff (PDF)

Molecular marker expression in oral and oropharyngeal squamous cell carcinoma

Archives of otolaryngology--head & neck surgery, 2001-07, Vol.127 (7), p.780

2001

Volltextzugriff (PDF)

1 – 25 von 96

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(91)
Mit Volltextzugriff
(85)

Publikationsform

Artikel
(95)
Tagungsberichte
(1)

Sprache

Englisch
(96)
Japanisch
(19)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR Her2 inhibitor in non-small-cell lung cancer cells

Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE

Activation (Tyrosine Phosphorylation) of ErbB-2 (HER-2/neu): A Study of Incidence and Correlation With Outcome in Breast Cancer

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Active signaling by Neu in transgenic mice

Adenoid cystic carcinoma: A retrospective clinical review

Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours

Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: Clinicopathological correlates

Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor

Pathobiologic Findings in DCIS of the Breast: Morphologic Features, Angiogenesis, HER-2/neu and Hormone Receptors

Drugs targeting insulin-like growth factor 1 receptor

Relationship of Epidermal Growth Factor Receptor Expression to ErbB-2 Signaling Activity and Prognosis in Breast Cancer Patients

Neoadjuvant Trastuzumab Induces Apoptosis in Primary Breast Cancers

Self-Management and Transitions in Women With Advanced Breast Cancer

Sequence of Radiotherapy With Tamoxifen in Conservatively Managed Breast Cancer Does Not Affect Local Relapse Rates

Abstract GS1-10: Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE

Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin)

Abstract P5-11-03: Development of an interactive text messaging tool to improve adherence with adjuvant endocrine therapy: Breast cancer endocrine therapy adherence (BETA) pilot study

Production of Antibodies That Recognize Specific Tyrosine‐Phosphorylated Peptides

Association between HER2/neu overexpression and calcifications in breast cancer

Histologic subtypes of ductal intraepithelial neoplasia (DIN) of the breast: Characteristic associations and biology

Characterization of the HER-2/neu Oncogene by Immunohistochemical and Fluorescence in Situ Hybridization Analysis in Oral and Oropharyngeal Squamous Cell Carcinoma

In vitro and in vivo effects of combination of trastuzumab (Herceptin) and tamoxifen in breast cancer

Abstract P3-14-17: Trastuzumab (H) and Rapamycin (R) for Treatment of HER-2 Overexpressing Metastatic Breast Cancer (BC) with Prior Disease Progression on H Based Therapy: Safety and Pharmacodynamic (PD) Results

Molecular marker expression in oral and oropharyngeal squamous cell carcinoma

Suchergebnisse filtern